samedan logo
 
 
spacer
home > epc > spring 2008 > don’t get lost in translation
PUBLICATIONS
European Pharmaceutical Contractor

Don’t Get Lost in Translation

Rob Sexstone of 3di Information Solutions explains that there’s more to language barriers than a matter of translation

NEW MARKET OPPORTUNITIES

The European marketplace continues to extend its borders as more and more countries within the EU trade with each other as well as with other nations throughout the world. New member countries like Bulgaria and Romania are joining the EU, and because high-skill, low-cost economies like China and India are expanding, they are importing, exporting and consuming at an exponential rate. The opening of these new markets, supported by increasing global affluence, is resulting in new opportunities and challenges for companies that sell medical diagnostic and patient-care technology products.

As we know, bringing a product to market, particularly a software-managed medical device, is a complex process in its own right. However, taking that new product into markets with different language and cultural requirements demands an even greater and more complex blend of knowledge and skills. The product software and user interface must be designed in such a way that they can be launched in new territories cost-efficiently and without compromising usability or functional stability.

For a product management team, the planning, quality assurance and version control of a software product in multiple languages can be very time-consuming and brings with it often unforeseen additional overheads. If the approach to this process is not considered and planned from the outset, it can mean failure or very late and expensive product releases.

When planning the launch of a product in a new territory, the product manager will often think of the language barrier as an obstacle that needs to be overcome. Some degree of planning needs to be involved to ensure that translation is scoped as part of the eventual product marketing roll-out. However, often the focus on solving only the translation challenge means that bigger challenges are missed.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Rob Sexstone is Head of Localisation and Language Technology at 3di Information Solutions Ltd. He specialises in process design and automation, localisation quality management and multilingual systems integration. Rob is a Member of the Institute for Scientific and Technical Communicators and has a BSc in Computational Linguistics from the University of Manchester.
spacer
Rob Sexstone
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement